search
Back to results

A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma

Primary Purpose

Glaucoma, Open-Angle, Ocular Hypertension

Status
Completed
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
Latanoprost
Sponsored by
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glaucoma, Open-Angle

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A patient with an IOP greater than or equal to 20 mmHg related to unilateral or bilateral OH or OAG (primary open angle glaucoma, pseudo-exfoliative glaucoma, and pigmentary glaucoma), after a visual field exam
  • Naive patients (i.e. never having been treated) and requiring treatment initiation

Exclusion Criteria:

  • A patient with OH or OAG currently on treatment
  • A patient with OH or OAG previously treated (regardless of the date treatment was discontinued)
  • A patient with traumatic, inflammatory, or neovascular glaucoma

Sites / Locations

  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site
  • Pfizer Investigational Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Latanoprost group

Arm Description

Outcomes

Primary Outcome Measures

Change in IOP after 3 months of treatment in absolute values (mmHg) compared to baseline IOP

Secondary Outcome Measures

Change in IOP after 3 months of treatment in relative values (percentage of decrease) compared to baseline IOP
Proportion of patients after 3 months of treatment with a relative reduction in IOP of greater than or equal to 30%, and greater than or equal to 10%
Change in IOP after 1 month of treatment in absolute (mmHg) and relative values (percentage of decrease) relative to baseline IOP
Proportion of patients after 1 month of treatment with a relative reduction in IOP of greater than or equal to 30%, and greater than or equal to 10%
Proportion of patients after 3 months of treatment achieving the following target IOP values: IOP less than or equal to 21 mmHg, IOP less than or equal to 18 mmHg, IOP less than or equal to 15 mmHg
Proportion of patients after 1 month of treatment achieving the following target IOP values: IOP less than or equal to 21 mmHg, IOP less than or equal to 18 mmHg, IOP less than or equal to 15 mmHg
Occurrence of adverse events on latanoprost, local tolerability analysis by clinical exam

Full Information

First Posted
March 26, 2008
Last Updated
February 1, 2021
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00647101
Brief Title
A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma
Official Title
Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg
Study Type
Interventional

2. Study Status

Record Verification Date
March 2008
Overall Recruitment Status
Completed
Study Start Date
December 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
February 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effect of latanoprost on intraocular pressure reduction in patients with ocular hypertension or open-angle glaucoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glaucoma, Open-Angle, Ocular Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
600 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Latanoprost group
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Latanoprost
Intervention Description
Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
Primary Outcome Measure Information:
Title
Change in IOP after 3 months of treatment in absolute values (mmHg) compared to baseline IOP
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Change in IOP after 3 months of treatment in relative values (percentage of decrease) compared to baseline IOP
Time Frame
3 months
Title
Proportion of patients after 3 months of treatment with a relative reduction in IOP of greater than or equal to 30%, and greater than or equal to 10%
Time Frame
3 months
Title
Change in IOP after 1 month of treatment in absolute (mmHg) and relative values (percentage of decrease) relative to baseline IOP
Time Frame
1 month
Title
Proportion of patients after 1 month of treatment with a relative reduction in IOP of greater than or equal to 30%, and greater than or equal to 10%
Time Frame
1 month
Title
Proportion of patients after 3 months of treatment achieving the following target IOP values: IOP less than or equal to 21 mmHg, IOP less than or equal to 18 mmHg, IOP less than or equal to 15 mmHg
Time Frame
3 months
Title
Proportion of patients after 1 month of treatment achieving the following target IOP values: IOP less than or equal to 21 mmHg, IOP less than or equal to 18 mmHg, IOP less than or equal to 15 mmHg
Time Frame
1 month
Title
Occurrence of adverse events on latanoprost, local tolerability analysis by clinical exam
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A patient with an IOP greater than or equal to 20 mmHg related to unilateral or bilateral OH or OAG (primary open angle glaucoma, pseudo-exfoliative glaucoma, and pigmentary glaucoma), after a visual field exam Naive patients (i.e. never having been treated) and requiring treatment initiation Exclusion Criteria: A patient with OH or OAG currently on treatment A patient with OH or OAG previously treated (regardless of the date treatment was discontinued) A patient with traumatic, inflammatory, or neovascular glaucoma
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Pfizer Investigational Site
City
Albi
ZIP/Postal Code
81000
Country
France
Facility Name
Pfizer Investigational Site
City
Ambert
ZIP/Postal Code
63600
Country
France
Facility Name
Pfizer Investigational Site
City
Amboise
ZIP/Postal Code
37400
Country
France
Facility Name
Pfizer Investigational Site
City
Angers
ZIP/Postal Code
49100
Country
France
Facility Name
Pfizer Investigational Site
City
Antibes
ZIP/Postal Code
06600
Country
France
Facility Name
Pfizer Investigational Site
City
Aubenas
ZIP/Postal Code
07200
Country
France
Facility Name
Pfizer Investigational Site
City
Belfort
ZIP/Postal Code
90000
Country
France
Facility Name
Pfizer Investigational Site
City
Bergerac
ZIP/Postal Code
24100
Country
France
Facility Name
Pfizer Investigational Site
City
Bernay
ZIP/Postal Code
27300
Country
France
Facility Name
Pfizer Investigational Site
City
Bethune
ZIP/Postal Code
62400
Country
France
Facility Name
Pfizer Investigational Site
City
Beziers
ZIP/Postal Code
34500
Country
France
Facility Name
Pfizer Investigational Site
City
Blagnac
ZIP/Postal Code
31700
Country
France
Facility Name
Pfizer Investigational Site
City
Bordeaux
ZIP/Postal Code
33000
Country
France
Facility Name
Pfizer Investigational Site
City
Bordeaux
ZIP/Postal Code
33100
Country
France
Facility Name
Pfizer Investigational Site
City
Bougival
ZIP/Postal Code
78380
Country
France
Facility Name
Pfizer Investigational Site
City
Boulogne-Billancourt
ZIP/Postal Code
92100
Country
France
Facility Name
Pfizer Investigational Site
City
Brest
ZIP/Postal Code
29200
Country
France
Facility Name
Pfizer Investigational Site
City
Bry Sur Marne
ZIP/Postal Code
94360
Country
France
Facility Name
Pfizer Investigational Site
City
Carentan
ZIP/Postal Code
50500
Country
France
Facility Name
Pfizer Investigational Site
City
Cenon
ZIP/Postal Code
33150
Country
France
Facility Name
Pfizer Investigational Site
City
Chamalieres
ZIP/Postal Code
63400
Country
France
Facility Name
Pfizer Investigational Site
City
Chantilly
ZIP/Postal Code
60500
Country
France
Facility Name
Pfizer Investigational Site
City
Chartres
ZIP/Postal Code
28000
Country
France
Facility Name
Pfizer Investigational Site
City
Chateaubriant
ZIP/Postal Code
44110
Country
France
Facility Name
Pfizer Investigational Site
City
Chateaulin
ZIP/Postal Code
29150
Country
France
Facility Name
Pfizer Investigational Site
City
Clermont-Ferrand
ZIP/Postal Code
63100
Country
France
Facility Name
Pfizer Investigational Site
City
Condom
ZIP/Postal Code
32100
Country
France
Facility Name
Pfizer Investigational Site
City
Coulommiers
ZIP/Postal Code
77120
Country
France
Facility Name
Pfizer Investigational Site
City
Courbevoie
ZIP/Postal Code
92400
Country
France
Facility Name
Pfizer Investigational Site
City
Creil
ZIP/Postal Code
60100
Country
France
Facility Name
Pfizer Investigational Site
City
Deauville
ZIP/Postal Code
14800
Country
France
Facility Name
Pfizer Investigational Site
City
Deuil la Barre
ZIP/Postal Code
95170
Country
France
Facility Name
Pfizer Investigational Site
City
Douai
ZIP/Postal Code
59500
Country
France
Facility Name
Pfizer Investigational Site
City
Draveil
ZIP/Postal Code
91210
Country
France
Facility Name
Pfizer Investigational Site
City
Enghien Les Bains
ZIP/Postal Code
95880
Country
France
Facility Name
Pfizer Investigational Site
City
Epernay
ZIP/Postal Code
51200
Country
France
Facility Name
Pfizer Investigational Site
City
Fontaine
ZIP/Postal Code
38600
Country
France
Facility Name
Pfizer Investigational Site
City
Frejus
ZIP/Postal Code
83600
Country
France
Facility Name
Pfizer Investigational Site
City
Gennevilliers
ZIP/Postal Code
92230
Country
France
Facility Name
Pfizer Investigational Site
City
Gradignan
ZIP/Postal Code
33170
Country
France
Facility Name
Pfizer Investigational Site
City
Grasse
ZIP/Postal Code
06130
Country
France
Facility Name
Pfizer Investigational Site
City
Grasse
ZIP/Postal Code
06135
Country
France
Facility Name
Pfizer Investigational Site
City
Grenoble
ZIP/Postal Code
38000
Country
France
Facility Name
Pfizer Investigational Site
City
Grenoble
ZIP/Postal Code
38100
Country
France
Facility Name
Pfizer Investigational Site
City
Guingamp
ZIP/Postal Code
22200
Country
France
Facility Name
Pfizer Investigational Site
City
Haguenau
ZIP/Postal Code
67500
Country
France
Facility Name
Pfizer Investigational Site
City
Herblay
ZIP/Postal Code
95220
Country
France
Facility Name
Pfizer Investigational Site
City
Hyeres
ZIP/Postal Code
83400
Country
France
Facility Name
Pfizer Investigational Site
City
Issy Les Moulineaux
ZIP/Postal Code
92130
Country
France
Facility Name
Pfizer Investigational Site
City
Ivry Sur Seine
ZIP/Postal Code
94210
Country
France
Facility Name
Pfizer Investigational Site
City
Jarville La Malgrange
ZIP/Postal Code
5414
Country
France
Facility Name
Pfizer Investigational Site
City
Joigny
ZIP/Postal Code
89300
Country
France
Facility Name
Pfizer Investigational Site
City
Juvisy Sur Orge
ZIP/Postal Code
91260
Country
France
Facility Name
Pfizer Investigational Site
City
La Rochelle
ZIP/Postal Code
17000
Country
France
Facility Name
Pfizer Investigational Site
City
La Talaudiere
ZIP/Postal Code
42350
Country
France
Facility Name
Pfizer Investigational Site
City
La Trinite
ZIP/Postal Code
06340
Country
France
Facility Name
Pfizer Investigational Site
City
Landerneau
ZIP/Postal Code
29800
Country
France
Facility Name
Pfizer Investigational Site
City
Langon
ZIP/Postal Code
33210
Country
France
Facility Name
Pfizer Investigational Site
City
Lannion
ZIP/Postal Code
22300
Country
France
Facility Name
Pfizer Investigational Site
City
Laon
ZIP/Postal Code
02000
Country
France
Facility Name
Pfizer Investigational Site
City
Le Creuzot
ZIP/Postal Code
71200
Country
France
Facility Name
Pfizer Investigational Site
City
Le Havre
ZIP/Postal Code
76600
Country
France
Facility Name
Pfizer Investigational Site
City
Le Mans
ZIP/Postal Code
72000
Country
France
Facility Name
Pfizer Investigational Site
City
Le Peage De Rousillon
ZIP/Postal Code
38550
Country
France
Facility Name
Pfizer Investigational Site
City
Le Quesnoy
ZIP/Postal Code
59530
Country
France
Facility Name
Pfizer Investigational Site
City
Lesneven
ZIP/Postal Code
29260
Country
France
Facility Name
Pfizer Investigational Site
City
Lille
ZIP/Postal Code
59000
Country
France
Facility Name
Pfizer Investigational Site
City
Livry Gargan
ZIP/Postal Code
93190
Country
France
Facility Name
Pfizer Investigational Site
City
Lunel
ZIP/Postal Code
34400
Country
France
Facility Name
Pfizer Investigational Site
City
Luneville
ZIP/Postal Code
54300
Country
France
Facility Name
Pfizer Investigational Site
City
Luxeuil les Bains
ZIP/Postal Code
70300
Country
France
Facility Name
Pfizer Investigational Site
City
Lyon
ZIP/Postal Code
69002
Country
France
Facility Name
Pfizer Investigational Site
City
Lyon
ZIP/Postal Code
69006
Country
France
Facility Name
Pfizer Investigational Site
City
Lyon
ZIP/Postal Code
69008
Country
France
Facility Name
Pfizer Investigational Site
City
Lyon
ZIP/Postal Code
69437
Country
France
Facility Name
Pfizer Investigational Site
City
Maisons Laffitte
ZIP/Postal Code
78600
Country
France
Facility Name
Pfizer Investigational Site
City
Marcq en Baroeul
ZIP/Postal Code
59700
Country
France
Facility Name
Pfizer Investigational Site
City
Marignanne
ZIP/Postal Code
13700
Country
France
Facility Name
Pfizer Investigational Site
City
Marseille
ZIP/Postal Code
13001
Country
France
Facility Name
Pfizer Investigational Site
City
Marseille
ZIP/Postal Code
13004
Country
France
Facility Name
Pfizer Investigational Site
City
Marseille
ZIP/Postal Code
13008
Country
France
Facility Name
Pfizer Investigational Site
City
MArseille
ZIP/Postal Code
13009
Country
France
Facility Name
Pfizer Investigational Site
City
Marseille
ZIP/Postal Code
13012
Country
France
Facility Name
Pfizer Investigational Site
City
Meyzieu
ZIP/Postal Code
69330
Country
France
Facility Name
Pfizer Investigational Site
City
Montauban
ZIP/Postal Code
82000
Country
France
Facility Name
Pfizer Investigational Site
City
Montceau Les Mines
ZIP/Postal Code
71300
Country
France
Facility Name
Pfizer Investigational Site
City
Montpellier
ZIP/Postal Code
34000
Country
France
Facility Name
Pfizer Investigational Site
City
Mulhouse
ZIP/Postal Code
68200
Country
France
Facility Name
Pfizer Investigational Site
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Name
Pfizer Investigational Site
City
Nice
ZIP/Postal Code
06000
Country
France
Facility Name
Pfizer Investigational Site
City
Nice
ZIP/Postal Code
06300
Country
France
Facility Name
Pfizer Investigational Site
City
Nimes Cedex 2
ZIP/Postal Code
30918
Country
France
Facility Name
Pfizer Investigational Site
City
Nimes
ZIP/Postal Code
30000
Country
France
Facility Name
Pfizer Investigational Site
City
Niort
ZIP/Postal Code
79000
Country
France
Facility Name
Pfizer Investigational Site
City
Nogent Sur Marne
ZIP/Postal Code
94130
Country
France
Facility Name
Pfizer Investigational Site
City
Noyon
ZIP/Postal Code
60400
Country
France
Facility Name
Pfizer Investigational Site
City
Orleans
ZIP/Postal Code
45000
Country
France
Facility Name
Pfizer Investigational Site
City
Oullins
ZIP/Postal Code
69600
Country
France
Facility Name
Pfizer Investigational Site
City
Pantin
ZIP/Postal Code
93500
Country
France
Facility Name
Pfizer Investigational Site
City
Paray le Monial
ZIP/Postal Code
71600
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75006
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75008
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75009
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75012
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75014
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75015
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75016
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75018
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75019
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75020
Country
France
Facility Name
Pfizer Investigational Site
City
Paris
ZIP/Postal Code
75116
Country
France
Facility Name
Pfizer Investigational Site
City
Pauillac
ZIP/Postal Code
33250
Country
France
Facility Name
Pfizer Investigational Site
City
Pau
ZIP/Postal Code
64000
Country
France
Facility Name
Pfizer Investigational Site
City
Perigueux
ZIP/Postal Code
24000
Country
France
Facility Name
Pfizer Investigational Site
City
Perros Girec
ZIP/Postal Code
22700
Country
France
Facility Name
Pfizer Investigational Site
City
Pezenas
ZIP/Postal Code
34120
Country
France
Facility Name
Pfizer Investigational Site
City
Poissy
ZIP/Postal Code
78300
Country
France
Facility Name
Pfizer Investigational Site
City
Poitiers
ZIP/Postal Code
86000
Country
France
Facility Name
Pfizer Investigational Site
City
Pont de Cheruy
ZIP/Postal Code
38230
Country
France
Facility Name
Pfizer Investigational Site
City
Pornic
ZIP/Postal Code
44210
Country
France
Facility Name
Pfizer Investigational Site
City
Port De Bouc
ZIP/Postal Code
13110
Country
France
Facility Name
Pfizer Investigational Site
City
Quimper
ZIP/Postal Code
29000
Country
France
Facility Name
Pfizer Investigational Site
City
Reims
ZIP/Postal Code
51100
Country
France
Facility Name
Pfizer Investigational Site
City
Rochefort
ZIP/Postal Code
17300
Country
France
Facility Name
Pfizer Investigational Site
City
Romilly sur Seine
ZIP/Postal Code
10100
Country
France
Facility Name
Pfizer Investigational Site
City
Saint Die des Vosges
ZIP/Postal Code
88100
Country
France
Facility Name
Pfizer Investigational Site
City
Saint Etienne
ZIP/Postal Code
42000
Country
France
Facility Name
Pfizer Investigational Site
City
Saint Gaudens
ZIP/Postal Code
31800
Country
France
Facility Name
Pfizer Investigational Site
City
Saint Savine
ZIP/Postal Code
10300
Country
France
Facility Name
Pfizer Investigational Site
City
Saintes
ZIP/Postal Code
17100
Country
France
Facility Name
Pfizer Investigational Site
City
Salon de Provence
ZIP/Postal Code
13300
Country
France
Facility Name
Pfizer Investigational Site
City
Sartrouville
ZIP/Postal Code
78500
Country
France
Facility Name
Pfizer Investigational Site
City
Sens
ZIP/Postal Code
89100
Country
France
Facility Name
Pfizer Investigational Site
City
Sessiney Pariset
ZIP/Postal Code
38170
Country
France
Facility Name
Pfizer Investigational Site
City
Sete
ZIP/Postal Code
34200
Country
France
Facility Name
Pfizer Investigational Site
City
Soissons
ZIP/Postal Code
02209
Country
France
Facility Name
Pfizer Investigational Site
City
St Chamond
ZIP/Postal Code
42200
Country
France
Facility Name
Pfizer Investigational Site
City
St Etienne
ZIP/Postal Code
42100
Country
France
Facility Name
Pfizer Investigational Site
City
St Michel Sur Orge
ZIP/Postal Code
91240
Country
France
Facility Name
Pfizer Investigational Site
City
St. Brieuc
ZIP/Postal Code
22015
Country
France
Facility Name
Pfizer Investigational Site
City
St. Lo
ZIP/Postal Code
50000
Country
France
Facility Name
Pfizer Investigational Site
City
Strasbourg
ZIP/Postal Code
67000
Country
France
Facility Name
Pfizer Investigational Site
City
Strasbourg
ZIP/Postal Code
67200
Country
France
Facility Name
Pfizer Investigational Site
City
Suresnes
ZIP/Postal Code
92150
Country
France
Facility Name
Pfizer Investigational Site
City
Talence
ZIP/Postal Code
33400
Country
France
Facility Name
Pfizer Investigational Site
City
Thiers
ZIP/Postal Code
63300
Country
France
Facility Name
Pfizer Investigational Site
City
Toulon
ZIP/Postal Code
83000
Country
France
Facility Name
Pfizer Investigational Site
City
Toulouse
ZIP/Postal Code
31500
Country
France
Facility Name
Pfizer Investigational Site
City
Toulouse
ZIP/Postal Code
34100
Country
France
Facility Name
Pfizer Investigational Site
City
Tourcoing
ZIP/Postal Code
59200
Country
France
Facility Name
Pfizer Investigational Site
City
Tournefeuille
ZIP/Postal Code
31170
Country
France
Facility Name
Pfizer Investigational Site
City
Tours
ZIP/Postal Code
37000
Country
France
Facility Name
Pfizer Investigational Site
City
Trelissac
ZIP/Postal Code
24750
Country
France
Facility Name
Pfizer Investigational Site
City
Tremblay en France
ZIP/Postal Code
93290
Country
France
Facility Name
Pfizer Investigational Site
City
Triel Sur Seine
ZIP/Postal Code
78510
Country
France
Facility Name
Pfizer Investigational Site
City
Troyes
ZIP/Postal Code
10000
Country
France
Facility Name
Pfizer Investigational Site
City
Valenciennes
ZIP/Postal Code
59300
Country
France
Facility Name
Pfizer Investigational Site
City
Vannes
ZIP/Postal Code
56000
Country
France
Facility Name
Pfizer Investigational Site
City
Vauvert
ZIP/Postal Code
30600
Country
France
Facility Name
Pfizer Investigational Site
City
Veauche
ZIP/Postal Code
42340
Country
France
Facility Name
Pfizer Investigational Site
City
Velaux
ZIP/Postal Code
13800
Country
France
Facility Name
Pfizer Investigational Site
City
Vendargues
ZIP/Postal Code
34740
Country
France
Facility Name
Pfizer Investigational Site
City
Venissieux Cedex
ZIP/Postal Code
69694
Country
France
Facility Name
Pfizer Investigational Site
City
Viarmes
ZIP/Postal Code
95270
Country
France
Facility Name
Pfizer Investigational Site
City
Vienne
ZIP/Postal Code
38200
Country
France
Facility Name
Pfizer Investigational Site
City
Villeneuve D'Ascq
ZIP/Postal Code
59650
Country
France
Facility Name
Pfizer Investigational Site
City
Villeneuve la Garenne
ZIP/Postal Code
92390
Country
France
Facility Name
Pfizer Investigational Site
City
Villeneuve Saint Georges
ZIP/Postal Code
94190
Country
France
Facility Name
Pfizer Investigational Site
City
Villeparisis
ZIP/Postal Code
77270
Country
France
Facility Name
Pfizer Investigational Site
City
Villepinte
ZIP/Postal Code
93420
Country
France
Facility Name
Pfizer Investigational Site
City
Villiers Le Bel
ZIP/Postal Code
95400
Country
France
Facility Name
Pfizer Investigational Site
City
Vizille
ZIP/Postal Code
38220
Country
France
Facility Name
Pfizer Investigational Site
City
Voiron
ZIP/Postal Code
38500
Country
France
Facility Name
Pfizer Investigational Site
City
Wattrelos
ZIP/Postal Code
59150
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
20181282
Citation
Denis P, Baudouin C, Bron A, Nordmann JP, Renard JP, Rouland JF, Sellem E, Amrane M. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmol. 2010 Feb 24;10:4. doi: 10.1186/1471-2415-10-4.
Results Reference
derived
Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6111002&StudyName=A%20Study%20to%20Assess%20the%20Efficacy%20of%203%20Months%20of%20Latanoprost%20Treatment%20in%20Reducing%20the%20Intraocular%20Pressure%20in%20Patients%20with%20Ocular%20Hyp
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma

We'll reach out to this number within 24 hrs